January 2025 in “ARC Journal of Dermatology” Black patients are underrepresented in alopecia research, highlighting the need for more inclusive studies.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.
44 citations
,
October 1989 in “International Journal of Pharmaceutics” Minoxidil's effectiveness decreases as vehicle evaporates; concentration and thermodynamic activity matter.
October 2024 in “Journal of the Endocrine Society” Estrogen alone can lower testosterone in some transfeminine people.
1 citations
,
January 2010 Finasteride is mainly broken down by the enzyme CYP3A4, affecting its levels in the body.
Reviewers suggested the study on finding new drug uses through social media side-effects needs better methods and clearer limitations.
February 2016 in “PubMed” Properly administered testosterone therapy is safe and effective but often not covered by insurance.
29 citations
,
December 2017 in “Molecular therapy” Enzyme replacement therapy improved multiple symptoms of homocystinuria in mice.
16 citations
,
June 2015 in “Drug Design Development and Therapy” The new formulation improves dutasteride's absorption when taken orally.
5 citations
,
February 2011 in “Expert Opinion on Drug Discovery” We need better treatments for hair loss, and while test-tube methods are helpful, they can't fully replace animal tests for evaluating new hair growth treatments.
October 2025 in “Dermatology and Therapy” Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
12 citations
,
July 2011 in “Experimental Dermatology” The ethosomal delivery system improves topical drug delivery and promotes hair growth.
November 2024 in “Pharmaceutics” Transfersomes are better than liposomes for targeting hair follicles in alopecia treatment.
May 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Biochanin A from soy is a promising and safe candidate for treating hair loss.
July 2013 in “Pharmaceutical Regulatory Affairs Open Access” Formulation F1 is the best for delivering finasteride effectively.
23 citations
,
January 1991 in “Journal of Animal Science” Biotin supplementation in sow diets is unnecessary.
2 citations
,
March 2014 in “European Journal of Chemistry” Method measures tamsulosin and finasteride in medicine accurately.
TrichoSol™ effectively stabilizes various hair treatment ingredients for different durations.
January 2026 in “Open Science Framework” Oral and topical 5-alpha reductase inhibitors affect DHT levels and hair density differently in treating hair loss.
March 2026 in “Journal of Veterinary and Animal Sciences” Supplements improved calves' haircoat condition.
1 citations
,
July 2025 in “Biomaterials Advances” 3D cultures respond better to minoxidil, while 2D cultures respond better to DHT.
20 citations
,
March 2005 in “Current Medicinal Chemistry” New compounds show promise for treating hair loss, enlarged prostate, and prostate cancer, with some being more effective and having different side effects than current treatments.
January 2023 in “Applied sciences” Equisetum debile extracts may help with skin whitening, anti-wrinkle, and anti-hair loss treatments.
December 2025 in “Molecules” A new method effectively detects trace sex hormones in cosmetics, ensuring safety.
April 2023 in “JMIR Research Protocols” The study aims to create a model to predict health attributes using diverse health data from Japanese adults.
29 citations
,
May 2013 in “Andrologia” Cross-sex hormone treatment in transsexual individuals helps understand how sex hormones affect diseases like heart disease and diabetes.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Disease-specific tools better assess quality of life in alopecia areata patients.
April 2019 in “Journal of the Endocrine Society” Using LC-MS/MS for hormone measurement can prevent false high testosterone results and avoid unnecessary tests.
23 citations
,
August 2018 in “Anais Brasileiros De Dermatologia” Both androgenetic alopecia and alopecia areata negatively impact quality of life, with no significant difference between them.
September 2018 in “Value in Health” Orphan drug benefit scores in Germany are influenced by phase III data and lack of alternatives, but not linked to price or discounts.